Efficacy of anti-Apolipoprotein A2 antibody on Kawasaki disease model mice

DOI
  • Ito Fuyu
    Asia International Institute of Infectious Disease Control, General Medical Education and Research Center, Teikyo University,
  • Suzuki Kazuo
    Research Institute of Disaster Medicine, Chiba University

Bibliographic Information

Other Title
  • 川崎病モデルマウスに対する抗ApolipoproteinA2 抗体の有効性

Abstract

High-dose intravenous immunoglobulin therapy (IVIg therapy) is effective for Kawasaki disease, a vasculitis syndrome. However due to issues that are associated with immunoglobulin preparation, such as the risk of possible contamination by infectious agents and limited blood banking resources, recombinant immunoglobulins are required. Therefore, we cloned recombinant IgG gene fragments from human lymphocytes, established a library, and selected one clone that was therapeutically effective at low doses using MPO-ANCA-related vasculitis model mice. We developed a novel recombinant antibody drug candidate, VasSF, and apolipoproteinA2 (APOA2) has been identified as one of VasSF's target molecules. Furthermore, we report that APOA2 was also found to be effective in Kawasaki disease model mice.

Journal

  • ROKiVA Letter

    ROKiVA Letter 4 (1), 4-8, 2024-04-01

    Research Organization for Kidney and Vascular Ageing

Keywords

Details 詳細情報について

  • CRID
    1390581489523005312
  • DOI
    10.60307/rokiva.4.1_4
  • ISSN
    24367842
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top